What could strengthen or challenge OneWater Marine, Inc.’s outlook?
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Higher potential upsideImproving expectations
Next-FY EPS estimate change · 30 days
Comparable estimates unavailable
+10% or more+5%0%−5%−10% or less
A matching fiscal period and sufficient coverage are required.
Higher risk of downsideWeakening expectations
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
How this is measured
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
Measure / period
Management expectations
Analyst expectations
FY 2027 · Q1
Revenue
—
382.64M
EPS
—
-0.425
FY 2026 · Annual
When factoring in the lost revenue
$1.78B–$1.88B
—
EPS
$0.35–$0.55non-GAAP
—
EBITDA
$68M–$78Mnon-GAAP
—
FY 2027 · Annual
Revenue
—
1.83B
EPS
—
1.187
FY 2028 · Annual
Revenue
—
1.98B
EPS
—
1.702
What the Thesis Depends On
4 published thesis conditions, with dated milestones shown separately.
Key Factor
Why It Matters
Current Status
Break Condition
Latest Evidence
Successful integration of Ocean Bio-Chem acquisition
A supporting condition in OneWater Marine, Inc.'s published investment case. The stated target is complete and accretive.
Intact
Acquisition fails to contribute positively by FY 2026
Direct metric needs a verified mapping
The published measure or accounting basis is not supported by an exact source binding.
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management context
Stated as a priority in 3 of last 3 quarters. Management has completed the sale of Ocean Bio-Chem, which impacted revenues and inventory levels. The divestiture proceeds supported debt repayment, indicating progress on acquisition-related strategic actions.
Delivery assessment Oct 24, 2026
Adjusted EBITDA of $60M-$80M for FY 2026
OneWater aims for adjusted EBITDA between $60M and $80M in 2026.
Improving
Adjusted EBITDA falls below $60M in FY 2026
Direct metric needs a verified mapping
The published measure or accounting basis is not supported by an exact source binding.
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management context
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA was $16.3 million in 2026-Q1, $16 million in 2026-Q2, and increased to $37.8 million in 2026-Q3, showing improvement. Management's guidance for fiscal 2026 remains $60 million to $80 million, indicating delivery on margin expansion and strengthening balance sheet.
Delivery assessment Oct 24, 2026
Revenue near $1.83 billion next quarter
Revenue is expected near $1.83 billion next quarter.
Broken
Revenue falls below $1.78B next quarter
Revenue: $530.711M
FY2026-Q3; GAAP. Published target: ~$1.83B. Target period ends 2026-09-30; this observation covers 2026-Q3.
Source published Jul 31, 2026530,711,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement source
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management context
Stated as a priority in 3 of last 3 quarters. Same-store sales declined 8% in 2026-Q2 and 2% in 2026-Q3, below the flat target. Management expects flat same-store sales for fiscal 2026 factoring in exited brands and divestitures, indicating mixed progress against the goal.
Delivery assessment Oct 24, 2026
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Incoming Evidence
Compare these dated observations with the operating requirements above
Expectations trend
Same fiscal period
FY2028 · fiscal year ending 2028-09-30 · fmp
FY2028 EPS: comparable history unavailable.
FY2028 revenue: comparable history unavailable.
Exact estimates & source dates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
FY2028 estimate observations · fmp
Snapshot
EPS
Revenue
EPS / revenue analysts
2026-10-01
Unavailable
Unavailable
2 / 1
2026-10-02
Unavailable
Unavailable
2 / 1
2026-10-03
Unavailable
Unavailable
2 / 1
2026-10-04
Unavailable
Unavailable
2 / 1
2026-10-05
Unavailable
Unavailable
2 / 1
2026-10-06
Unavailable
Unavailable
2 / 1
2026-10-07
Unavailable
Unavailable
2 / 1
2026-10-08
Unavailable
Unavailable
2 / 1
2026-10-09
Unavailable
Unavailable
2 / 1
2026-10-10
Unavailable
Unavailable
2 / 1
2026-10-11
Unavailable
Unavailable
2 / 1
2026-10-12
Unavailable
Unavailable
2 / 1
2026-10-13
Unavailable
Unavailable
2 / 1
2026-10-14
Unavailable
Unavailable
2 / 1
2026-10-15
Unavailable
Unavailable
2 / 1
2026-10-16
Unavailable
Unavailable
2 / 1
2026-10-17
Unavailable
Unavailable
2 / 1
2026-10-18
Unavailable
Unavailable
2 / 1
2026-10-19
Unavailable
Unavailable
2 / 1
2026-10-20
Unavailable
Unavailable
2 / 1
2026-10-21
Unavailable
Unavailable
2 / 1
2026-10-22
Unavailable
Unavailable
2 / 1
2026-10-23
Unavailable
Unavailable
2 / 1
2026-10-24
Unavailable
Unavailable
2 / 1
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
How this is measured
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Outlook in Brief
The evidence, the remaining questions, and what comes next
What's improving
No recovery evidence is reported in the available driver assessments.
Still unresolved / key risks
Successful integration of Ocean Bio-Chem acquisitionDirect metric needs a verified mapping
Adjusted EBITDA of $60M-$80M for FY 2026Direct metric needs a verified mapping
Revenue near $1.83 billion next quarterPublished status: Broken
Maintain flat dealership same-store sales for FY 2026Direct metric needs a verified mapping
Next proof point
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Risk observations as of Oct 23, 2026 · 277 daily observations. Historical moves are not forecasts.
Read detailed Outlook Company context, assumptions & risks
OneWater Marine, Inc. outlook in detail
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
What kind of bet this is
This is a high-risk turnaround and execution story, not a proven durable compounder, because the company is loss-making. The multi-year view has some support from improving adjusted EBITDA and lower leverage, but recent performance remains below its industry cohort.
What's priced into OneWater Marine, Inc.
ONEW is rated cheap versus peers, and the pricing tag is justified, with no fragility warning fired. However, valuation-model confidence is low, and the negative expectations gap points to weak expectations rather than clear evidence that the business has turned around.
What the fundamentals likely do
Near term, earnings risk is elevated: recent results included two earnings misses, and the estimated miss probability is 58%. Adjusted EBITDA improved to $37.8 million in 2026-Q3, and net debt leverage reached 3.7x, but same-store sales still declined 2% in that quarter, below management’s flat-sales goal.
What OneWater Marine, Inc. hinges on
For the rest of fiscal 2026, the key test is whether management reaches its $60 million to $80 million adjusted EBITDA goal while bringing same-store sales toward flat. A guidance cut would be a meaningful negative; continued earnings strength from sector bellwethers could support the consumer discretionary backdrop, while weaker results from those companies could remove that support.
Bottom line
Over the next 1 to 3 years, the long-term thesis depends on sustained margin improvement, lower leverage, and better sales execution. The valuation is cheap versus peers, but high risk, recent misses, and low valuation confidence leave the thesis unresolved. Not investment advice.
Source: QuarterlyIQ weekly Outlook · Week ending Oct 24, 2026 · Carried forward
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
